136.66 USD
-0.67
0.49%
Updated Aug 26, 11:26 AM EDT
1 day
-0.49%
5 days
-0.39%
1 month
-5.95%
3 months
-2.31%
6 months
-6.37%
Year to date
-8.78%
1 year
-11.69%
5 years
56.15%
10 years
79.53%
 

About: DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

Employees: 76,000

0
Funds holding %
of 7,431 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

4.07% more ownership

Funds ownership: 88.78% [Q1] → 92.85% (+4.07%) [Q2]

8% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 62

2% less funds holding

Funds holding: 588 [Q1] → 579 (-9) [Q2]

8% less capital invested

Capital invested by funds: $10.9B [Q1] → $9.98B (-$879M) [Q2]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]

23% less repeat investments, than reductions

Existing positions increased: 180 | Existing positions reduced: 234

51% less call options, than puts

Call options by funds: $86.1M | Put options by funds: $175M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$160
17%
upside
Avg. target
$160
17%
upside
High target
$160
17%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Barclays
Andrew Mok
17%upside
$160
Equal-Weight
Maintained
7 Aug 2025

Financial journalist opinion

Based on 13 articles about DVA published over the past 30 days

Negative
Reuters
4 days ago
Ransomware attack at dialysis firm DaVita affects 2.7 million people, US health dept website shows
A ransomware attack that encrypted certain elements of dialysis firm DaVita's network affected 2.7 million people, the U.S. health department's website showed on Thursday.
Ransomware attack at dialysis firm DaVita affects 2.7 million people, US health dept website shows
Positive
Seeking Alpha
6 days ago
DaVita: Aggressive Buybacks Despite Rising Cost Of Debt
DaVita has reduced the share count by over 10% in the last six months, but interest expenses increased by 50% Y/Y. International revenues grew by 36% Y/Y, and DaVita is pending regulatory approval to close an acquisition from Fresenius Medical Care AG in Brazil. In the U.S., volumes declined by 1.1% Y/Y during Q2 2025 due to missed treatments caused by the severe flu season and the April cyber attack.
DaVita: Aggressive Buybacks Despite Rising Cost Of Debt
Positive
The Motley Fool
1 week ago
2 Warren Buffett Stocks to Buy Hand Over Fist and 1 to Avoid
Warren Buffett is one of the most celebrated investors of our time. The famed chief executive officer of Berkshire Hathaway, who will celebrate his 95th birthday on Aug. 30, is finally retiring from the conglomerate after a 60-year career in which he made Berkshire one of the biggest publicly traded companies in the world.
2 Warren Buffett Stocks to Buy Hand Over Fist and 1 to Avoid
Positive
Zacks Investment Research
2 weeks ago
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
Positive
Zacks Investment Research
2 weeks ago
Are Investors Undervaluing DaVita (DVA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing DaVita (DVA) Right Now?
Neutral
Zacks Investment Research
2 weeks ago
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
DVA reports strong second-quarter 2025 results with earnings and revenue beat, along with a boost in gross margin, driven by core operations.
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
Neutral
Seeking Alpha
2 weeks ago
DaVita Inc. (DVA) Q2 2025 Earnings Call Transcript
DaVita Inc. (NYSE:DVA ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Javier J. Rodriguez - CEO & Executive Director Joel Ackerman - CFO & Treasurer Nic Eliason - Group Vice President of Investor Relations Conference Call Participants Albert J.
DaVita Inc. (DVA) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
2 weeks ago
DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates
DaVita HealthCare (DVA) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.7 per share. This compares to earnings of $2.59 per share a year ago.
DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates
Positive
Reuters
2 weeks ago
DaVita beats quarterly profit on steady demand for dialysis services
DaVita beat Wall Street estimates for second-quarter profit on Tuesday, driven by demand for its kidney dialysis services.
DaVita beats quarterly profit on steady demand for dialysis services
Neutral
PRNewsWire
2 weeks ago
DaVita Inc. 2nd Quarter 2025 Results
DENVER , Aug. 5, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2025. "We're reporting another solid quarter, fueled by our unwavering focus on patient care," said Javier Rodriguez, CEO of DaVita Inc. "We continued to deliver exceptional clinical outcomes for our patients, fostered a positive experience for our caregivers, and delivered on our financial commitments with disciplined execution across our businesses.
DaVita Inc. 2nd Quarter 2025 Results
Charts implemented using Lightweight Charts™